TSXV - Delayed Quote CAD

NervGen Pharma Corp. (NGEN.V)

Compare
3.0900
+0.1100
+(3.69%)
At close: January 10 at 3:59:49 PM EST
Currency in CAD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
23,000.9690
17,776.7100
23,025.0330
12,811.2240
11,195.8840
Operating Income
-23,000.9690
-17,776.7100
-23,025.0330
-12,811.2240
-11,195.8840
Net Non Operating Interest Income Expense
764.0520
550.0740
-313.2030
29.4170
18.8520
Other Income Expense
-1,768.7440
-5,155.4840
2,615.9530
55.2290
-9.1090
Pretax Income
-24,005.6610
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Net Income Common Stockholders
-24,005.6610
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Diluted NI Available to Com Stockholders
-24,005.6610
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Basic EPS
-0.38
-0.38
-0.39
-0.32
-0.35
Diluted EPS
-0.38
-0.38
-0.39
-0.32
-0.35
Basic Average Shares
64,715.1500
59,290.0470
52,649.0350
39,289.2240
32,111.6980
Diluted Average Shares
64,715.1500
59,290.0470
52,649.0350
39,289.2240
32,111.6980
Total Expenses
23,000.9690
17,776.7100
23,025.0330
12,811.2240
11,195.8840
Net Income from Continuing & Discontinued Operation
-24,005.6610
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Normalized Income
-22,236.9170
-17,226.6360
-23,338.2360
-12,781.8070
-11,177.0320
Interest Income
764.0520
550.0740
201.3960
29.4170
18.8520
Interest Expense
--
--
514.5990
--
--
Net Interest Income
764.0520
550.0740
-313.2030
29.4170
18.8520
EBIT
-27,606.3790
-22,382.1200
-20,207.6840
-12,726.5780
-11,195.8840
EBITDA
-27,499.7700
-22,237.1180
-20,092.5700
-12,683.9520
-11,156.2390
Reconciled Depreciation
106.6090
145.0020
115.1140
42.6260
39.6450
Net Income from Continuing Operation Net Minority Interest
-24,005.6610
-22,382.1200
-20,722.2830
-12,726.5780
-11,186.1410
Total Unusual Items Excluding Goodwill
-1,768.7440
-5,155.4840
2,615.9530
55.2290
-9.1090
Total Unusual Items
-1,768.7440
-5,155.4840
2,615.9530
55.2290
-9.1090
Normalized EBITDA
-25,731.0260
-17,081.6340
-22,708.5230
-12,739.1810
-11,147.1300
12/31/2020 - 3/15/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MSCL.TO Satellos Bioscience Inc.
0.8500
+1.19%
 
CWBR CohBar, Inc.
0.4100
0.00%
 
CTNM Contineum Therapeutics, Inc.
13.29
-0.60%
 
RZLT Rezolute, Inc.
4.9000
-5.95%
 
EPRX Eupraxia Pharmaceuticals Inc.
3.0000
-1.64%
 
MSCLF Satellos Bioscience Inc.
0.6130
+2.17%
 
FRX.TO Fennec Pharmaceuticals Inc.
8.59
-2.05%
 
GSD.V Devonian Health Group Inc.
0.1650
0.00%
 
NRXBF NUREXONE BIOLOGIC INC
0.4550
+2.00%
 
SBM.V Sirona Biochem Corp.
0.0600
-7.69%